Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

[Development of fluorescent probes for detecting reactive sulfur species and their application to development of inhibitors for 3MST].

Echizen H, Hanaoka K.

Nihon Yakurigaku Zasshi. 2019;154(3):121-127. doi: 10.1254/fpj.154.121. Japanese.

PMID:
31527361
2.

[A Retrospective Evaluation of the Impact of Multi-disciplinary Approach for Improving the Quality of Anticoagulation Therapy in Ambulatory Patients with Non-valvular Atrial Fibrillation Receiving Warfarin].

Ohgushi A, Nakayama N, Namiki A, Nagashima A, Ogawa R, Akazawa M, Echizen H.

Yakugaku Zasshi. 2019;139(9):1177-1183. doi: 10.1248/yakushi.18-00209. Japanese.

3.

Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life.

Nakayama H, Suzuki M, Kato T, Echizen H.

Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):837-843. doi: 10.1007/s13318-019-00564-w.

PMID:
31154618
4.
5.

Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery.

Asada M, Nagata M, Mizuno T, Uchida T, Kurashima N, Takahashi H, Makita K, Arai H, Echizen H, Yasuhara M.

Pharmacol Res Perspect. 2018 Nov 5;6(6):e00440. doi: 10.1002/prp2.440. eCollection 2018 Dec.

6.

Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life.

Nakayama H, Echizen H, Ogawa R, Orii T, Kato T.

Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):77-82. doi: 10.1007/s13318-018-0495-5.

PMID:
30027304
7.

Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature.

Nango D, Nakashima H, Hirose Y, Shiina M, Echizen H.

J Pharm Health Care Sci. 2018 May 31;4:14. doi: 10.1186/s40780-018-0111-5. eCollection 2018.

8.

Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.

Hirai T, Itoh T, Kimura T, Echizen H.

Br J Clin Pharmacol. 2018 Oct;84(10):2260-2269. doi: 10.1111/bcp.13666. Epub 2018 Jul 8.

9.

Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.

Murakoso K, Minagawa R, Echizen H.

J Pharm Health Care Sci. 2018 Mar 20;4:5. doi: 10.1186/s40780-018-0103-5. eCollection 2018.

10.

Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study.

Tatsuzawa M, Ogawa R, Kinjo N, Kim S, Shimizu F, Sakamoto Y, Shimojima K, Echizen H, Miyazaki A.

Clin Med Insights Oncol. 2017 Oct 30;11:1179554917737736. doi: 10.1177/1179554917737736. eCollection 2017.

11.

Authors' reply to Dr. Bailey's commentary: Predicting clinical relevance of grapefruit-drug interactions: A complicated process.

Takahashi M, Echizen H.

J Clin Pharm Ther. 2017 Dec;42(6):800-801. doi: 10.1111/jcpt.12591. Epub 2017 Jul 11. No abstract available.

PMID:
28695578
12.

Fluorescent Probes and Selective Inhibitors for Biological Studies of Hydrogen Sulfide- and Polysulfide-Mediated Signaling.

Takano Y, Echizen H, Hanaoka K.

Antioxid Redox Signal. 2017 Oct 1;27(10):669-683. doi: 10.1089/ars.2017.7070. Epub 2017 May 18. Review.

13.

Induration at Injection or Infusion Site May Reduce Bioavailability of Parenteral Phenobarbital Administration.

Nakayama H, Echizen H, Ogawa R, Akabane A, Kato T, Orii T.

Ther Drug Monit. 2017 Jun;39(3):297-302. doi: 10.1097/FTD.0000000000000391.

PMID:
28328763
14.

Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) - Digest Version.

Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchishita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, Sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K; Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group.

Circ J. 2017 Mar 24;81(4):581-612. doi: 10.1253/circj.CJ-66-0138. Epub 2017 Mar 9. No abstract available.

15.

Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.

Shibata S, Takahashi H, Baba A, Takeshita K, Atsuda K, Matsubara H, Echizen H.

Int J Clin Pharmacol Ther. 2017 May;55(5):449-452. doi: 10.5414/CP202764.

PMID:
28157069
16.

Impact of Pharmacists' audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study.

Shimizu T, Momose Y, Ogawa R, Takahashi M, Echizen H.

J Pharm Health Care Sci. 2017 Jan 17;3:4. doi: 10.1186/s40780-017-0077-8. eCollection 2017.

17.

Correlations between the enantio- and regio-selective metabolisms of warfarin.

Takahashi H, Ohara M, Shibata S, Lee MT, Cavallari LH, Nutescu EA, Scordo MG, Pengo V, Padrini R, Atsuda K, Matsubara H, Chen YT, Echizen H.

Pharmacogenomics. 2017 Jan;18(2):133-142. doi: 10.2217/pgs-2016-0149. Epub 2016 Dec 20.

PMID:
27995809
18.
19.

Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis.

Funahashi K, Koyano S, Echizen H, Matsubara T.

Mod Rheumatol. 2017 Mar;27(2):271-277. doi: 10.1080/14397595.2016.1206172. Epub 2016 Jul 14.

PMID:
27416107
21.
22.

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study.

Ohgushi A, Ohtani T, Nakayama N, Asai S, Ishii Y, Namiki A, Akazawa M, Echizen H.

J Pharm Health Care Sci. 2016 Jan 11;2:2. doi: 10.1186/s40780-015-0036-1. eCollection 2016.

24.

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Echizen H.

Clin Pharmacokinet. 2016 Apr;55(4):409-18. doi: 10.1007/s40262-015-0326-7. Review.

PMID:
26369775
25.

Predictive performance of three practical approaches for grapefruit juice-induced 2-fold or greater increases in AUC of concomitantly administered drugs.

Takahashi M, Onozawa S, Ogawa R, Uesawa Y, Echizen H.

J Clin Pharm Ther. 2015 Feb;40(1):91-7. doi: 10.1111/jcpt.12231. Epub 2014 Nov 4.

PMID:
25365914
26.

Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Ogawa R, Stachnik JM, Echizen H.

Clin Pharmacokinet. 2014 Dec;53(12):1083-114. doi: 10.1007/s40262-014-0189-3. Review.

PMID:
25248847
27.

Simultaneous determination of N(1)-methylnicotinamide, L-carnitine, and creatinine in human plasma and urine by liquid chromatography with mass spectrometry for assessing the activities of multiple renal cationic transporters.

Nobuoka Y, Ogawa R, Echizen H.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15;967:240-4. doi: 10.1016/j.jchromb.2014.07.034. Epub 2014 Aug 2.

PMID:
25129409
28.

Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis.

Shibata S, Takahashi H, Ono N, Wada N, Kubo H, Shinozaki K, Saito H, Inamoto N, Machida M, Atsuda K, Echizen H.

J Clin Pharm Ther. 2014 Apr;39(2):181-5. doi: 10.1111/jcpt.12127. Epub 2014 Jan 10.

PMID:
24405193
29.

Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.

Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H.

Int J Clin Pharmacol Ther. 2013 May;51(5):357-66. doi: 10.5414/CP201739.

PMID:
23458228
30.

Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Ogawa R, Stachnik JM, Echizen H.

Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2. Review.

PMID:
23344981
31.

Acute kidney injury after myeloablative cord blood transplantation in adults: the efficacy of strict monitoring of vancomycin serum trough concentrations.

Mae H, Ooi J, Takahashi S, Kato S, Kawakita T, Ebihara Y, Tsuji K, Nagamura F, Echizen H, Tojo A.

Transpl Infect Dis. 2013 Apr;15(2):181-6. doi: 10.1111/tid.12038. Epub 2012 Dec 20.

PMID:
23279721
32.

Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.

Ichimura Y, Takahashi H, Lee MT, Shiomi M, Mihara K, Morita T, Chen YT, Echizen H.

Clin Pharmacokinet. 2012 Dec;51(12):799-808. doi: 10.1007/s40262-012-0009-6.

PMID:
23018470
33.

Clinically significant drug interactions with antacids: an update.

Ogawa R, Echizen H.

Drugs. 2011 Oct 1;71(14):1839-64. doi: 10.2165/11593990-000000000-00000. Review.

PMID:
21942976
34.

Drug-drug interaction profiles of proton pump inhibitors.

Ogawa R, Echizen H.

Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000. Review.

PMID:
20608754
35.

A novel microsatellite polymorphism of sodium channel beta1-subunit gene (SCN1B) may underlie abnormal cardiac excitation manifested by coved-type ST-elevation compatible with Brugada syndrome in Japanese.

Ogawa R, Kishi R, Takagi A, Sakaue I, Takahashi H, Matsumoto N, Masuhara K, Nakazawa K, Kobayashi S, Miyake F, Echizen H.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):109-19.

PMID:
20137763
36.

Urinary lipocalin-type prostaglandin D synthase: a potential marker for early gentamicin-induced renal damage?

Nakayama H, Echizen H, Gomi T, Shibuya Y, Nakamura Y, Nakano K, Arashi H, Itai T, Ohnishi S, Tanaka M, Orii T.

Ther Drug Monit. 2009 Feb;31(1):126-30. doi: 10.1097/FTD.0b013e31819566f1.

PMID:
19125150
37.

Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.

Nakayama H, Echizen H, Tanaka M, Sato M, Orii T.

Ther Drug Monit. 2008 Feb;30(1):103-7. doi: 10.1097/FTD.0b013e318164f781.

PMID:
18223471
38.
39.

Proteomic and transcriptomic analyses of retinal pigment epithelial cells exposed to REF-1/TFPI-2.

Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):516-21.

PMID:
17251444
40.

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H.

Ann Pharmacother. 2007 Jan;41(1):21-8. Epub 2007 Jan 2.

PMID:
17200426
41.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H.

Pharmacogenet Genomics. 2006 Feb;16(2):101-10.

PMID:
16424822
42.

Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.

Ogawa R, Kishi R, Mihara K, Takahashi H, Takagi A, Matsumoto N, Masuhara K, Nakazawa K, Miyake F, Kobayashi S, Echizen H.

J Clin Pharmacol. 2006 Jan;46(1):59-68.

PMID:
16397285
43.

In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.

Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I.

J Clin Pharmacol. 2005 Nov;45(11):1221-9.

PMID:
16239354
44.

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. 1984.

Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M.

Br J Clin Pharmacol. 2004 Dec;58(7):S796-803; discussion S804-6. No abstract available.

45.

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.

Takahashi H, Wilkinson GR, Padrini R, Echizen H.

Clin Pharmacol Ther. 2004 May;75(5):376-80. Review. No abstract available.

PMID:
15116049
46.

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H.

Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30.

PMID:
15070684
49.

The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man.

Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T.

J Pharm Pharmacol. 2003 Nov;55(11):1553-9.

PMID:
14713367

Supplemental Content

Loading ...
Support Center